Protocol No. CAMN107AUS37: "Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 after Switching to Nilotinib"

  • Markowitz, Avi (PI)

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date3/26/13 → 12/31/20

    Funding

    • Novartis Pharmaceuticals Corporation: $94,543.00